Stryker Corporation, based in Portage, Michigan, is a leading medical technology company with a market cap of $143.4 billion. They offer innovative products in MedSurg, Neurotechnology, Orthopaedics, and Spine, impacting over 150 million patients annually in nearly 75 countries.

Despite reaching an all-time high of $406.19 on Jan. 28, Stryker’s stock has dropped 5.6% in the past three months, underperforming the Health Care Select Sector SPDR Fund’s 15.6% surge. Over the longer term, SYK stock is up 3.4% YTD but down 4.5% over the past year.

After reporting better-than-expected Q3 results, Stryker’s stock prices fell 3.5%. Organic sales increased 9.5% year-over-year, with net sales up 10.3% to $6.1 billion. Adjusted EPS surged 11.1% to $3.19. Despite the initial dip, SYK stock saw positive momentum in subsequent trading sessions.

Analysts rate Stryker stock a “Moderate Buy” with a mean price target of $434.32, suggesting a 16.7% upside potential. Stryker has underperformed compared to Boston Scientific Corporation, with 13% YTD gains.

Read more at Yahoo Finance: Is SYK Underperforming the Healthcare Sector?